43rd week of 2009 patent applcation highlights part 33 |
Patent application number | Title | Published |
20090263322 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES - The invention features substituted fused bicyclic compounds, pharmaceutical compositions containing them, and methods of using them to treat or prevent histamine-mediated diseases and conditions. | 2009-10-22 |
20090263323 | Novel means and methods for the treatment of hearing loss and phantom hearing - This invention relates to a method of identifying a modulator of an NADPH oxidase, whereby said modulator is suitable as a lead compound and/or as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing, the method comprising the steps of (a) contacting a test compound with a protein, wherein said protein (i) comprises or consists of the amino acid sequence of any one of SEQ ID NO: 1, 3 or 5, or (ii) is encoded by a nucleic acid comprising or consisting of the sequence of any one of SEQ ID NO: 2, 4, 6, 23 or 24, or (iii) is a fragment of the protein according to (i) or (ii) and exhibits NADPH oxidase activity, or (iv) has a sequence at least 75% identical with the protein according to (i) or (ii) or with the fragment according to (iii) and exhibits NADPH oxidase activity, and optionally with one or more NADPH oxidase subunits, under conditions allowing binding of said test compound to said protein or, if present, said subunit(s); (b) optionally determining whether said test compound binds to said protein or, if present, said subunit(s); and (c) determining whether (ca) said test compound, upon contacting in step (a); or (cb) said test compound, upon binding in step (b) modulates the expression and/or activity of said protein or, if present, said subunit(s). Also provided are pharmaceutical compositions, medical uses and diagnostic uses of compounds of the invention. | 2009-10-22 |
20090263324 | Animal Model With Induced Arrhythmia - Provided are a model animal physiologically similar to humans, enabling a highly reproducible evaluation of the onset of drug-induced long QT syndrome, a method of generating the same, and an evaluating method using the same. A proarrhythmia model animal of a monkey, prepared by ablating the atrioventricular node; the foregoing monkey is preferably a cynomolgus monkey. A method of generating a proarrhythmia model animal, comprising a step for inserting an electrode catheter to the heart of a monkey, and ablating atrioventricular node with the catheter, and a method of evaluating the QT interval prolongation by a drug, comprising using the foregoing model animal. | 2009-10-22 |
20090263325 | METHOD AND APPARATUS FOR THE DISSOLUTION AND FILTRATION OF A HYPERPOLARIZED AGENT WITH A NEUTRAL DISSOLUTION MEDIA - Methods and apparatuses that facilitate dissolving a hyperpolarized agent within a polarizer and transporting it to a receiver is provided. The methods include delivering water to a hyperpolarized agent contained within a polarizer, forming a hyperpolarized aqueous solution, transporting the aqueous solution through a fluid path system out of the polarizer, filtering the aqueous solution through a partical size exclusion filter to a receiver, and modifying the pH of the filtered hyperpolarized aquous solution with a dissolution medium contained in the receiver. Also disclosed herein are apparatuses for dissolving a hyperpolarized agent comprising a vial for containing a hyperpolarized imaging agent therein, a dissolution fluid path, a delivery fluid path, a particle size exclusion filter, and a receiver connected to the particle size exclusion filter and positioned to receive the filtered aqueous solution of the hyperpolarized imaging agent. | 2009-10-22 |
20090263326 | NANO-SCALE CONTRAST AGENTS AND METHODS OF USE - Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution. | 2009-10-22 |
20090263327 | MINIMALLY INVASIVE PHYSIOLOGICAL FUNCTION MONITORING AGENTS - Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo. | 2009-10-22 |
20090263328 | FLUORESCENCE OBSERVATION APPARATUS AND FLUOROSCOPY METHOD - A site of interest to be observed is clearly observed in an image during fluoroscopy of a small laboratory animal, even when the fluorescence is extremely low. The invention provides a fluorescence observation apparatus including a light source that emits excitation light; an optical system that irradiates an image-acquisition site on a small laboratory animal with the excitation light from the light source; a light-blocking unit that blocks light in a prescribed region of the small laboratory animal or in an image of the prescribed region; an image-acquisition unit that acquires a fluorescence image of the small laboratory animal; and a control unit configured to identify a high-fluorescence region having a prescribed fluorescence level or above in the fluorescence image of the small laboratory animal acquired by the image-acquisition unit and to control the light-blocking unit so as to block light at the identified high-fluorescence region. | 2009-10-22 |
20090263329 | CELL LABELING WITH PERFLUOROCARBON NANOPARTICLES FOR MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY - Methods of obtaining cells internally labeled with perfluorocarbon nanoparticles suitable for magnetic resonance imaging and spectroscopy are disclosed. Also disclosed are methods for obtaining magnetic resonance imaging data from labeled under clinically relevant scan times and field strengths. Finally, the application further discloses methods of specifically detecting and distinguishing magnetic resonance imaging and spectroscopy data from two distinct sets of cells labeled with distinct types of perfluorocarbon nanoparticles. | 2009-10-22 |
20090263330 | GAS-FILLED MICROVESICLES WITH POLYMER-MODIFIED LIPIDS - Image enhancing contrast agents for use in diagnostic and/or therapeutic methods, particularly in the form of gas-filled microvesicles, with enhanced stability. The gas-filled microvesicles are stabilized by a layer of amphiphilic material and comprise from 0.15% to 1.0% by moles of a lipid bearing a hydrophilic polymer. The lipid bearing a hydrophilic polymer is preferably a phospholipid linked to polyethyleneglycol. | 2009-10-22 |
20090263331 | MULTIFUNCTION NANOCONJUGATES FOR IMAGING APPLICATIONS AND TARGETED TREATMENT - The present invention relates to nanoconjugates. In particular, the present invention provides nanoconjugates for diagnostic (e.g., imaging), research, and clinical (e.g., targeted treatment) applications. | 2009-10-22 |
20090263332 | POLYMER PARTICLE CONTAINING PARAMAGNETIC METAL COMPOUND - A magnetic resonance imaging agent which includes: a polymer containing the structural unit represented by the following formula (I) and the structural unit represented by the following formula (II) in a molar ratio of 5 to 80:20 to 95; a paramagnetic metal compound; and a ligand molecule: | 2009-10-22 |
20090263333 | Pharmaceutical compounds and compositions - The invention provides three polymorphic forms of crystalline levosalbutamol sulphate designated herein as Forms I, II and III. Crystalline levosalbutamol sulphate Form I is characterised by a powder XRD pattern with peaks at 10.8, 11.9, 13.0, 18.3, 28.5±0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form II is characterised by a powder XRD pattern with peaks at 8.7, 9.6, 15.2, 15.7, 19.1, 27.2, 30.7±0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form III is characterised by a powder XRD pattern with peaks at 5.5, 6.9, 7.3, 18.7±0.2 degrees 2 theta. Processes for making the new polymorphic forms and pharmaceutical compositions comprising them are also provided. A pharmaceutical composition comprises a therapeutically effective isomer of salbutamol or a salt, solvate, ester, derivative or polymorph thereof, a glucocorticoid and a pharmaceutically acceptable carrier or excipient and optionally one or more other therapeutic agents. Preferably the composition is an aerosol formulation comprising the drugs, a propellant and optionally one or more other ingredients, such as a surfactant, cosolvent, or bulking agent. Alternatively, DPI or inhalation suspensions may be used. | 2009-10-22 |
20090263334 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals - Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat cognitive disorders as well as manufacture of medicaments including tablets, capsules, injectable solutions that are useful for treatment of such conditions. | 2009-10-22 |
20090263335 | USE OF AEROSOLIZED CYCLOSPORINE FOR PREVENTION AND TREATMENT OF PULMONARY DISEASE - The present invention relates to methods and compositions for prevention of graft rejection in lung transplant recipients and for treatment of subjects with pulmonary disorders. Specifically, the methods and compositions of the invention provide a means for inhibiting immune response mediated inflammatory processes in the lungs. The method of the invention comprises the administration of aerosolized cyclosporine for prevention of acute and/or chronic refractory rejection in lung transplant patients. The invention further provides for the use of aerosolized cyclosporine to treat subjects having immunologically mediated inflammatory pulmonary disorders including, but not limited to, asthma, cystic fibrosis, idiopathic pulmonary fibrosis, chronic bronchitis and allergic rhinitis. The present invention, by enabling a method for the use of aerosolized cyclosporine for inhibiting pulmonary inflammation leading to prevention of graft rejection and treatment of pulmonary disorders, provides a safer and less toxic treatment than those methods that utilize systemic administration of cyclosporine. | 2009-10-22 |
20090263336 | NOVEL PYRAN DERIVATIVES AND THEIR PREPARATION - A process of preparing a compound of formula (I) | 2009-10-22 |
20090263337 | DETERSIVE COMPOSITIONS CONTAINING HYDROPHOBIC BENEFIT AGENTS PRE-EMULSIFIED USING SUB-MICROMETER-SIZED INSOLUBLE CATIONIC PARTICLES - A cationic oil-in-water emulsion, for addition to detersive compositions, comprising hydrophilic cationic polymers, a surface-active, anionic polymer that is capable of adsorbing at an air-water interface or an oil-water interface and/or is oil-soluble, and a hydrophobic benefit agent in the oil phase made by adding the benefit agent to a hydrophobic liquid; thickening the oil phase with an organophillic smectite clay reacted at clay platelet surfaces to make the clay platelet surfaces hydrophobic while the edge surfaces of the clay remain hydrophilic, such that the organophillic smectite clay is adsorbed at an oil/water interface in the emulsion, and one of the hydrophilic, cationic polymers has a cationic nitrogen content of at least 6% by weight, that is incompatible with anionic surfactants, being insoluble in anionic-surfactant solutions containing an amount of 3% or higher of an anionic surfactant, and another hydrophilic cationic polymer has a cationic nitrogen content of at least 0.1% by weight and has a molecular weight of at least 600,000 Dalton. | 2009-10-22 |
20090263338 | NAIL VARNISH - Nail varnish composition in the form of an emulsion containing one or more water-soluble or water-dispersible polymers obtained from acrylamido-2-methylpropanesulphonic acid (or AMPS) or from one of its salts and from water-soluble monomers having ethylenic unsaturation(s) as gelling agent. Makeup method employing the composition. Dried films of the nail varnish. | 2009-10-22 |
20090263339 | AGENT FOR EXTERNAL APPLICATION TO THE SKIN - The present invention has an object to provide an agent for suppressing melanin production and/or inhibiting elastase activity containing a plant extract as an effective substance with high safety and acceptable levels of stability and odor or sediment formation and an agent for external application to the skin comprising the above agent which has excellent effects in skin-whitening and skin-beautifying. The object is attained by providing an agent for external application to the skin containing indigo-plant extract. | 2009-10-22 |
20090263340 | COSMETIC COMPOSITIONS - The present invention relates to cosmetic or dermatological compositions comprising salicylic acid, optionally substituted salicylic acid and/or derivatives thereof and ascorbic acid and/or derivatives thereof in a cosmetically acceptable carrier. The salicylic acid, optionally substituted salicylic acid and/or derivatives thereof serve as skin penetration enhancer for the ascorbic acid and/or derivatives thereof into human skin. The compositions are especially useful as skin lightening agents, anti-acne agents or anti-ageing agents. | 2009-10-22 |
20090263341 | SOFT ANTICHOLINERGIC ESTERS - Soft anticholinergic esters of the formulas: | 2009-10-22 |
20090263342 | Non-Lathering Personal Care Composition in the Form of an Article - A non-lathering personal care article in the form of a porous dissolvable solid structure, comprising: from about 0% to about 10% ionic surfactant; from about 1% to about 60% of a non-surfactant cosmetic active; from about 15% to about 70% polymeric structurant, wherein the polymeric structurant has a weighted average molecular weight of from about 40,000 to about 500,000; and from about 1% to about 30% plasticizer. The article has a density of from about 0.03 g/cm3 to about 0.15 g/cm3. | 2009-10-22 |
20090263343 | Deodorized cloth and method for deodorizing cloth - Disclosed is a deodorized cloth which is produced by applying a deodorizing agent comprising active carbon and an amine compound in two layers on a cloth, thereby providing a durable deodorizing property against any type of odor to the cloth. Also disclosed is a method for deodorization processing of a cloth. A resin composition comprising active carbon is applied as the first layer, and a resin composition comprising a deodorizing agent comprising an amine compound is applied as the second layer. In the resin composition for use as the first layer, a mixture of a deodorizing agent comprising a metal compound and a flame retardant agent may be used. Preferably, the resin composition for use as the second layer is applied in a dot-like pattern. | 2009-10-22 |
20090263344 | Perfume Compositions - Perfume compositions effective against urine malodour and having a low odour, comprise between 20% and 50% of perfume ingredients comprising at least 15% by-weight of N-ethyl-N-(3-methylphenyl) propanamide. | 2009-10-22 |
20090263345 | Otic compositions for the treatment of infections of the internal and external ear in mammals - Disclosed herein compositions including povidone-iodine (PVP-I) useful in the treatment of acute and chronic bacterial, viral and fungal infections of the internal, middle and external ear of mammals, including humans. | 2009-10-22 |
20090263346 | Systems and methods for delivery of drugs - Systems and methods for delivering drugs. Crystalline polymeric systems, referred to as CYC carriers, are associated with the drugs, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively low and sharp melting temperatures. One class of CYC carriers, referred to as CYSC polymers, have a majority of the crystallizable side chains pendant from the polymer backbone. Another class of CYC carriers, referred to as ECC polymers, have a majority of the crystallizable side chains attached to terminal units of the polymer backbone. The ECC polymers can for example be obtained by modification of PLGA polymers. The CYC carriers in another class are non-polymeric. Some CYC carriers, referred to as CYC assemblies, have enhanced crystallinity as a result of the physical association of crystallizable moieties which are present in different types of molecule, for example between a polymer containing crystallizable moieties and a monomer containing crystallizable moieties. Preferably the CYC carrier is bioerodable. | 2009-10-22 |
20090263347 | ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS - Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. In some cases, the methods entail treating the co-polymer with pyro-glutamate aminopeptidase to cleave N-terminal pyro-glutamate residues. | 2009-10-22 |
20090263348 | Nucleic Acids Encoding Multimeric Fusion Proteins of TNF Superfamily Ligands - A method for constructing stable bioactive fusion proteins of the difficult to express turn or necrosis factor superfamily (TNFSF), and particularly members CD40L (CD 154) and RANKL/TRANCE, with collecting, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these soluble fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be especially useful when these proteins are injected locally as a vaccine adjuvant or tumor immunotherapy agent to prevent them from diffusing away. In addition, these and other TNFSF-collectin fusion proteins present new possibilities for the expression of highly active, multimeric, soluble TNFSF members. | 2009-10-22 |
20090263349 | METHODS AND COMPOSITIONS FOR INHIBITING ANGIOGENESIS - The present invention relates to a method of inhibiting angiogenesis in a biological system. The method includes administering to the biological system an effective amount of a steroid saponin. | 2009-10-22 |
20090263350 | COSMETIC AND DERMATOLOGICAL METHODS - The present invention relates to cosmetic and dermatological methods for treating cellulite, reducing signs of aging skin, and treating stretch marks, the methods comprising applying/administering to the skin of a subject in need thereof the compositions comprising interleukin-1 alpha. | 2009-10-22 |
20090263351 | Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases - Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease. | 2009-10-22 |
20090263352 | METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-29 CYSTEINE MUTANTS - IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections. | 2009-10-22 |
20090263353 | Novel Sulphonylpyrroles as Inhibitors of Hdac S Novel Sulphonylpyrroles - Compounds of a certain formula I, | 2009-10-22 |
20090263354 | Compositions and siRNAs for inhibiting C/EBPbeta - The invention relates to C/EBPβ and modulation of cell resistance or sensitivity to triggers of cell death. More particular, it provides pharmaceutical compositions and siRNAs for inhibiting C/EBPβ thus decreasing resistance or enhancing sensitivity of cancer cells to a cancer therapy. | 2009-10-22 |
20090263355 | DEAMIDATED INTERFERON-BETA - Interferon-β protein analogs in which the asparagine at position 25, numbered in accordance with native interferon-β, is deamidated exhibit a biological activity of native human interferon-β at an increased level and do not require HA for protein stabilization. The deamidated product is suitable for large scale manufacturing for incorporation in HA-containing or HA-free therapeutics for treatment of diseases including multiple sclerosis. An endoproteinase-C peptide map technique that produces a fingerprint profile for proteins using an enzymatic digest followed by RP-HPLC is also useful in quality control as an ID and/or quantitative test for the deamidated products. | 2009-10-22 |
20090263356 | ANTI-ANGIOGENIC COMPOSITION COMPRISING GRAIN-DERIVED COMPONENT AS ACTIVE INGREDIENT - It is an object of the invention to provide a composition with an excellent action of inhibiting vascularization, as prepared by a simple method suitable for actual production from an inexpensive, relatively readily available material without any problematic safety profile at an industrial scale without any complicated purification step. The composition is a composition for inhibiting vascularization, which contains a barley-derived ingredient selected from the group consisting of an unpolished barley ethyl alcohol extract fraction, an unpolished barley alkali extract fraction and fermented barley (preferably, a residual solution from the distillation of barley distilled spirits) as the active component with an action of inhibiting vascularization. The composition for inhibiting vascularization is a composition for therapeutically treating or preventing diseases which vascularization should be inhibited, specifically diseases with an etiology of abnormal vascularization in tumor or cancer, chronic inflammation or retinopathy. The composition is in a form selected from the group consisting of food additives, food materials, foods and drinks, pharmaceutical products under regulations by the Ministry of Health and Labor in Japan and quasi-pharmaceutical products under regulations by the Ministry of Health and Labor in Japan, and feeds. | 2009-10-22 |
20090263357 | Therapeutic Reprogramming, Hybrid Stem Cells and Maturation - Therapeutically programmed cells and methods for making such cells are provided. Therapeutically programmed cells are stem cells which have been matured such that they represent either a more differentiated state or a less differentiated state after contact with stimulatory factors. The therapeutically reprogrammed cells are suitable for cellular regenerative therapy and have the potential to differentiate into more committed cell lineages. Additionally, hybrid stem cells suitable for therapeutic reprogramming and cellular regenerative therapy are provided. | 2009-10-22 |
20090263358 | METHOD FOR TREATING MULTIPLE MYELOMA - The present invention relates to methods for the treatment of multiple myeloma. More particularly, the present invention relates to a method for inducing apoptosis in myeloma cells by administration of a K121-like antibody. | 2009-10-22 |
20090263359 | Particulate Delivery Vehicles for Embryoid Bodies - The present invention provides a vehicle for delivering various chemicals, compositions and proteins to stem cells and embryoid bodies. The vehicle may be biocompatible and biodegradable polymer microparticles. Typically the particles will contain at least a growth factor for delivery to the embryoid bodies, and generally the growth factor induces differentiation of the cells in the embryoid body along a specific lineage. The present invention also provides methods for directing differentiation of the cells in the embryoid body. | 2009-10-22 |
20090263360 | Neuronal progenitors from feeder-free human embryonic stem cell culture - The present invention relates to methods for producing feeder cell-free neuroprogenitor cells (preferably adherent) from embryonic stems cells, preferably human embryonic stem cells, the feeder cell-free neuroprogenitor cells, preferably human cells themselves, as well as methods for producing feeder cell-free samples of neuronal cells, preferably adherent human neuronal cells and the feeder cell-free neuronal cells themselves. Pharmaceutical compositions and methods of treating neurodegenerative diseases as well as the use of the described cells in assay systems is also described. | 2009-10-22 |
20090263361 | HUMAN TROPHOBLAST STEM CELLS AND USE THEREOF - Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could be apply to human cell differentiation and for gene and cell-based therapies. | 2009-10-22 |
20090263362 | FERTILITY ENHANCEMENT USING LIPID CARRIERS AND BIOACTIVE MOLECULES - The invention relates to a composition and method for enhancing fertilization. Fertilization enhancement is achieved by effectively delivering bioactive molecules with a lipid anchor (GPI-linked proteins) to the surface of epididymal or ejaculated sperm. The process may be facilitated or promoted in the presence of Clusterin/APOJ, a well-known lipid carrier. The rate of delivery, or removal, of bioactive molecules is regulated by the concentration of lipid carrier present. The acquisition of these molecules, such as Sperm Adhesion Molecule 1 (SPAM1) can significantly impact sperm maturation and function. | 2009-10-22 |
20090263363 | Compositions and Methods For Treating Bone Formation Disorders - The present invention relates to compositions and methods for the detecting, treating, and empirically investigating disorders associated with bone formation (e.g., osteoporosis). In particular, the present invention provides compositions and methods for using maspin and targets of maspin in the diagnosis, treatment, and empirical investigation of disorders associated with bone formation (e.g., osteoporosis). | 2009-10-22 |
20090263364 | Method and constructs for delivering double stranded rna to pest organisms - The present invention relates in generally to RNAi and its use in gene silencing. In particular, the present invention relates to methods and constructs for delivering double stranded RNA (dsRNA) to pest organisms. | 2009-10-22 |
20090263365 | Methods and compositions for transforming dendritic cells and activating cells - Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen presenting cell which activates T cells against MHC class I-antigen targets. Kits, assays and therapeutics are based upon the activation of T cells by the recombinant dendritic cell. Cancer, viral infections and parasitic infections are all ameliorated by the recombinant dendritic cells, or corresponding activated T cells. Therapeutic compositions and pharmaceutical compositions are provided. | 2009-10-22 |
20090263366 | Effects of probiotics on humans and animals under environmental or biological changes - An exemplary embodiment providing one or more improvements includes probiotic compositions comprising probiotic microorganisms with dried vegetable, fruit, cereal, or herb powder. Feeding human or animals either having biological or environmental changes with probiotic compositions has a positive effect in relieving the changes. Positive effects has been demonstrated in humans, dogs, and fish. | 2009-10-22 |
20090263367 | COMPOSITION AND METHOD FOR PROMOTING INTERNAL HEALTH AND EXTERNAL APPEARANCE - The present invention relates to a new composition comprising substances that promote DNA repair, reduce body fat levels and increase lean body mass and that decrease wrinkle appearance and/or improvement in skin surface. In some aspects, the composition of the present invention include resveratrol, forskohlin and astaxanthin. In another aspect the composition of the present invention further comprises carboxy alkyl ester. The present invention also relates to a method of promoting internal health and external appearance in a subject in need, said method comprising administering to the subject a composition that promotes DNA repair, reduces body fat levels and increases lean body mass and that decreases wrinkle appearance and/or improvement in skin surface. | 2009-10-22 |
20090263368 | Genetic variations associated with psychiatric disorders - The present invention relates to a method for determining likelihood of an individual of developing a psychiatric disorder. More particularly, the method of the invention is based on the identification of genetic variations in genes involved in the modulation of melatonin and their consequences on such pathway for the determination of whether an individual is susceptible of being afflicted by a psychiatric disorder such as autism spectrum disorders (ASD), Deficits and Hyper Activity Disorder (ADHD) and anorexia. | 2009-10-22 |
20090263369 | Compositions of Prokaryotic Phenylalanine Ammonia-Lyase and Methods of Treating Cancer Using Compositions Thereof - The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic purposes, including the treatment of cancer. | 2009-10-22 |
20090263370 | METHODS FOR TREATING TACHYKININ-MEDIATED DISEASES WITH CHOLINESTERASE - Methods for treating or preventing a tachykinin-mediated disease, a skin disorder, or a symptom thereof in a mammal by administering to a mammal in need thereof cholinesterase or a pharmaceutical composition of cholinesterase. | 2009-10-22 |
20090263371 | Use Polysaccharides for Promotion of Enzymatic Activity - This disclosure provides methods and compositions for the promotion of enzymatic activity of Target Enzymes, including but not limited to oligosaccharide/polysaccharide enzymes, protein enzymes, polynucleotide enzymes. The methods involve use of a non-naturally occurring polysaccharide (including but not limited HES) for promoting the enzymatic activity of an enzyme in liquid milieu, wherein the concentration of the polysaccharide in the composition comprising the Target Enzyme is from about 0.01% to about 55% w/v. | 2009-10-22 |
20090263372 | PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF THE SYMPTOMS OF ADDICTION AND METHOD OF DIAGNOSING SAME - A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed. | 2009-10-22 |
20090263373 | NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE - The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire | 2009-10-22 |
20090263374 | METHOD OF PREVENTING AND TREATING BRAIN INFARCTION - The present invention is intended to clarify the relationship between PAR-2 and cerebral infarction and thereby provide an efficient method of preventing and treating cerebral infarction, as well as a pharmaceutical composition therefore. Namely, the present invention relates to a method of preventing and treating cerebral infarction by activating PAR-2 and/or promoting expression of PAR-2 gene. The present invention further relates to a pharmaceutical composition for preventing and treating cerebral infarction, comprising one, or two or more of the active ingredients selected from the group consisting of a PAR-2 activator and/or a PAR-2 gene expression promoter; as well as a pharmaceutically acceptable carrier. It further relates to a method of screening an active ingredient for preventing and treating cerebral infarction using as an indicator the PAR-2 activation promoted by a test substance. | 2009-10-22 |
20090263375 | NOVEL POLY(A) POLYMERASE - The present invention relates to novel poly(A) polymerases and their use in the treatment of diseases, disorders and conditions. More specifically, the poly(A) polymerases of the present invention include polymerases which are directly modulated by components of the phosphoinositide signaling pathway. Such components may include phosphatidylinositol phosphate kinases and phosphoinositide second messengers. | 2009-10-22 |
20090263376 | Breaking immunological toterance with a genetically encoded unnatural amino acid - The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against a version of a target moiety having one or more unnatural amino acid which antibody is cross reactive with the natural target moiety. | 2009-10-22 |
20090263377 | IL-32B-TARGETED DIAGNOSIS AND THERAPY - Methods for the diagnosis and treatment of IL-32β over-expressing cancers are provided. Also provided are methods for the treatment of wounds, hair loss and the promoting and/or restoration of hair growth utilized IL-32β antagonists. Finally, a sepsis model utilizing IL-32β is provided, as are methods for treating sepsis and inflammation using IL-32β antagonists. | 2009-10-22 |
20090263378 | METHODS OF IDENTIFYING ANTI-INFLAMMATORY COMPOUNDS - A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing IVIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a DC-SIGN | 2009-10-22 |
20090263379 | MONOCLONAL ANTIBODIES FOR INHIBITION OF LAMININ-8 EXPRESSION TO INHIBIT HUMAN GLIOMAS - Using gene array technology, we observed that an increase of the alpha-4 chain-containing Laminin-8 correlated with poor prognosis for patients with brain gliomas. We established that inhibition of Laminin-8 expression by a new generation of highly specific and stable antisense oligonucleotides (Morpholino™) against chains of Laminin-8 could slow or stop the spread of glioma. This was demonstrated in an in vitro model using human glioblastoma multiforme cell lines M059K and U-87MG co-cultured with normal human brain microvascular endothelial cells (HBMVEC). Using Western blot analysis and immunohistochemistry, we confirmed that antisense treatment effectively blocked laminin-8 protein synthesis. Antisense oligonucleotides against both alpha-4 and β1 chains of laminin-8 blocked significantly the invasion of co-cultures through Matrigel. The results show that Laminin-8 may not only contribute to glioma progression and recurrence as part of the neovascularization process but also by directly increasing the invasive potential of tumor cells. | 2009-10-22 |
20090263380 | ANTI-IDIOTYPIC ANTIBODIES NEUTRALIZING THE INHIBITORY ACTIVITY OF AN INHIBITORY ANTIBODY DIRECTED AGAINST THE C1 DOMAIN OF FACTOR VIII - The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the C1 domain of Factor VIII, as well as to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as medicament, and more particularly to the use thereof for manufacturing a medicament intended for the treatment of haemophilia A. | 2009-10-22 |
20090263381 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH AN ANTI-IGE ANTIBODY FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anti-IgE antibody for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. | 2009-10-22 |
20090263382 | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF ALPHA - The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNFα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNFα, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNFα-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed. | 2009-10-22 |
20090263383 | Antibodies to angiogenesis inhibiting domains of CD148 - The present invention provides compositions and methods relating to anti-CD148 receptor antibodies. Methods provided include inhibiting angiogenesis and, thereby, vascularization of solid tumors in human patients. The present invention also provides compositions and methods for in vivo imaging of tumors expressing CD148. Compositions of the invention include: anti-CD148 antibodies, antigen binding regions of anti-CD148 antibodies, polynucleotides encoding anti-CD 148 antibodies or binding regions thereof, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions is also provided. | 2009-10-22 |
20090263384 | Agents for Suppressing the Induction of Cytotoxic T Cells - The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6 receptor antibody was also administered to recipients of a mouse model for allogenic heart transplantation. As a result, histopathological findings showed that inflammatory cell infiltration into transplanted hearts was suppressed and the survival period of transplanted hearts was significantly prolonged. Thus, the present inventors for the first time discovered that administration of anti-IL-6 receptor antibodies could suppress cytotoxic T cell induction and thereby suppress acute rejection after transplantation. | 2009-10-22 |
20090263385 | Breast carcinoma treatment method - The instant invention is an in-vivo treatment method directed against living epithelial cells in the human breast, and uses a modified ductal lavage technique to infuse a purposely formulated treatment fluid into pre-chosen individual ducts in the human breast for reaction with such epithelial cells as then are present within the ducts. The prepared treatment fluid, at a minimum, comprises: at least one preselected Complement-fixing antibody (or preferably an admixture of different Complement-fixing antibodies) directed at specific antigens, haptens or epitopes which are characteristically present on normal, atypical, or malignant breast epithelial cells in-vivo; the recognized chemical components for activating and fixing Complement in-situ; and a biocompatible fluid carrier. The treatment method can be employed as a therapeutic process in-vivo against a presently existing breast disorder, neoplasm, or carcinoma; but also may be used in-vivo as a preventative procedure performed prophylactically in advance of the patient receiving a clinical diagnosis of breast malignancy (e.g., ductal, medullary, or lobular carcinoma). It can also be used to treat a breast with atypia, premalignancy, carcinoma in-situ, or carcinoma (when not treated with total mastectomy), and can be used as a prophylactic treatment in the contralaterial breast. | 2009-10-22 |
20090263386 | HUMANIZED IMMUNOMODULATORY MONOCLONAL ANTIBODIES FOR THE TREATMENT OF NEOPLASTIC DISEASE OR IMMUNODEFICIENCY - The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from an immune deficiency. | 2009-10-22 |
20090263387 | Neutralization of GM-CSF for the Treatment of Heart Failure - This invention relates to methods of treating a patient suffering from heart failure, or a patient at risk for heart failure, using a GM-CSF antagonist. | 2009-10-22 |
20090263388 | Methods of preventing or treating cardiovascular, cerebrovascular and thrombotic disorders with tumor necrosis factor antagonists - A method of treating or preventing a cardiovascular and/or a cerebrovascular disorder in an individual is disclosed. Also disclosed is a method for treating and/or preventing a thrombotic disorder in an individual. Further disclosed is a method of decreasing plasma fibrinogen in an individual. | 2009-10-22 |
20090263389 | Use of TGF-Beta Antagonists to Treat or to Prevent Chronic Transplant Rejection - Effective use of a TGF-β antagonist to treat or to prevent loss of transplant function is described herein. Use of a TGF-β antagonist is demonstrated to effectively prevent loss of organ function in a host due to chronic rejection in which TGF-β-mediated fibroproliferation is a characteristic. Expression in situ of a TGF-β antagonist in the form of a recombinant receptor, i.e., TGF-β type III receptor (TGFBIIIR) showed prevention of bronchiolitis obliterans in comparison to untreated controls in a rat lung transplant model. This provides an effective method for preventing or inhibiting chronic rejection of transplant organs such as lung, kidney, liver and heart in vertebrate hosts including human hosts. | 2009-10-22 |
20090263390 | METHOD OF TREATING CANCER BY CO-ADMINISTRATION OF ANTICANCER AGENTS - The present invention relates to a method of treating cancer by co-administration of an effective amount of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin -2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide and an effective amount of one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or a retuximab-containing combination therapy selected from R-ICE and R-DHAP. The treatment method of the present invention is useful for the treatment for all solid tumors and lymphomas, preferably skin cancer, bladder cancer, breast cancer, uterine cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer and the like. Particularly, they are expected as therapeutic agents for tumor types which show resistance against existing anticancer agents. | 2009-10-22 |
20090263391 | ANTIBODIES THAT BIND TO EPHA2 AND METHODS OF USE THEREOF - Provided herein is disclosure about the development and characterization of an antibody that binds to antigen EphA2 which is present on a variety of human cancers from breast, lung, prostate, and colons. Methods of diagnosing and treating various cancers by using such antibodies directed against this antigen are also disclosed. | 2009-10-22 |
20090263392 | METHODS OF MODIFYING ANTIBODIES FOR PURIFICATION OF BISPECIFIC ANTIBODIES - The present inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column based on the difference in isoelectric points between the H chains of two types of antibodies, wherein the difference is introduced by modifying the amino acids present on the surface of the antibody variable regions of two types of antibodies that constitute a bispecific antibody. Furthermore, the inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column by linking respective antigen binding sites (heavy chain variable regions) to the antibody constant regions having different isoelectric points, and then coexpressing these antibodies. | 2009-10-22 |
20090263393 | Methods of using(+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyr- rolidinyl]-4 -oxo-1-(2-thiazolyl)- 1,8-naphthyridine-3-carboxylic acid for treatment of cancer - Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed. | 2009-10-22 |
20090263394 | A34 AND A33-LIKE 3 DNA PROTEIN, ANTIBODIES THERETO AND METHODS OF TREATMENT USING SAME - Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33-like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient. | 2009-10-22 |
20090263395 | GENES AND POLYPEPTIDES RELATING TO BREAST CANCERS - The present application provides novel human genes B1194, A2282V1, A2282V2, and A2282V3 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer. | 2009-10-22 |
20090263396 | INHIBITORS OF T-DARPP FOR USE IN COMBINATION ANTI-CANCER THERAPIES - The present invention relates to an improved anti-HER2/Neu therapy comprising co-administration of an inhibitor of t-DARPP activity. In addition, inhibitors of t-DARPP can act as a monotherapy against cancers that express elevated t-DARPP activity, including elevated t-DARPP levels, or in combination with chemo- or radiotherapeutic anti-cancer treatments drugs. | 2009-10-22 |
20090263397 | Combination anti-cancer therapy - The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor of Formula (I) (e.g. OSI-906). Examples of such anti-cancer agents or treatments include doxorubicin, cisplatin, and ionizing radiation. The present invention also provides a pharmaceutical composition comprising an anti-cancer agent that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor of Formula (I), in a pharmaceutically acceptable carrier. The present invention also provides a method of identifying tumor cells that will respond most favorably to treatment with a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor. | 2009-10-22 |
20090263398 | PHARMACEUTICAL COMBINATIONS - The invention provides a combination comprising an ancillary compound and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R | 2009-10-22 |
20090263399 | METHOD FOR ESTABLISHING THE SENSITIVITY OF TUMOURS TO CAPECITABIN AND TEST KIT - The invention relates to a method for establishing the sensitivity of tumors towards capecitabine, if applicable in combination with Docetaxel or Paclitaxel or the humanized antibody Herceptin, or COX-2 inhibitors or angiogenesis inhibitors and test kit. | 2009-10-22 |
20090263400 | OSTEOPOROSIS ASSOCIATED MARKERS AND METHODS OF USE THEREOF - Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers. | 2009-10-22 |
20090263401 | USES OF IL-174 ANTAGONISTS FOR INHIBITING A Th2 IMMUNE RESPONSE - Agonists or antagonists of cytokine designated IL-174, and various methods of their use are provided. In particular, the methods make use of facts that many activities of the IL-174 cytokine are described. | 2009-10-22 |
20090263402 | Growth Differentiation Factor-11 - A transgenic non-human animal of the species selected from the group consisting of avian, bovine, ovine and porcine having a transgene which results in disrupting the production of and/or activity of growth differentiation factor-11 (GDF-11) chromosomally integrated into the germ cells of the animal is provided. Also provided are methods for making such animals, and methods of treating animals, including humans, with antibodies or antisense directed to GDF-11. The animals so treated are characterized by increased muscle tissue and bone tissue. | 2009-10-22 |
20090263403 | MAMMALIAN CELL MEMBRANE PROTEINS; RELATED REAGENTS - The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells, e.g., lymphoid and myeloid, are provided, along with methods for their use. | 2009-10-22 |
20090263404 | Methods and Compositions for Using MHC Class II Invariant Chain Polypeptide as a Receptor for Macrophage Migration Inhibitory Factor - Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | 2009-10-22 |
20090263405 | CpG OLIGONUCLEOTIDE PRODRUGS, COMPOSITIONS THEREOF AND ASSOCIATED THERAPEUTIC METHODS - The present invention provides a CpG oligonucleotide prodrug that includes a thermolabile substituent on at least one nucleotide thereof. The present invention also provides compositions that include a carrier and a therapeutically effective amount of at least one CpG oligonucleotide prodrug. The present invention further provides therapeutic methods of using such thermolabile CpG oligonucleotide prodrugs and compositions thereof. The present invention further provides a method of inhibiting tetrad formation in a CpG oligonucleotide by functionalizing the CpG oligonucleotide with one or more thermolabile substituents. | 2009-10-22 |
20090263406 | JY-1 Regulation Of Granulosa Cell Function And Early Embryonic Development In Cattle - The present invention provides compositions and methods for regulating fertility in mammals. In general, the invention relates to a novel protein produced by oocytes named JY-1, and nucleic acids encoding the JY-1 protein, for controlling folliculogenesis and early embryonic development, particularly in monoovulatory species. In particular, the present invention provides nucleic acid and amino acid sequences encoding JY-1, vectors for the expression of JY-1, host cells expressing JY-1, RNAi probes for reducing levels of JY-1 message, and antibodies to JY-1. Specifically, developing and mature oocytes express JY-1 in vivo, while granulosa cells treated in vitro with recombinant JY-1 (rJY-1) protein reduced cell proliferation while increasing progesterone synthesis and estradiol production. Further, reducing JY-1 protein in developing embryos in vitro using inhibitory siRNA constructs corresponded with arrested blastocyte maturation. | 2009-10-22 |
20090263407 | Cationic Lipids and Uses Thereof - Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed. | 2009-10-22 |
20090263408 | FORMULATION AND PRESENTATION OF MEDICAMENTS - A medicament package ( | 2009-10-22 |
20090263409 | CANCER ANTIGEN PEPTIDE FORMULATIONS - Cancer antigen peptides derived from WT 1 which have an in vivo efficacy, particularly a clinical usefulness, and cancer vaccines as dosage forms suitable for said cancer antigen peptides, are provided. | 2009-10-22 |
20090263410 | USE OF TGF-B1 INHIBITOR PEPTIDES IN THE PREPARATION OF AN IMMUNE RESPONSE MODULATING AGENT - The present invention relates to the use of a peptide inhibiting TGF-β1 selected from: peptide p144 whose sequence corresponds to SEQ ID NO: 1, peptide p17 whose sequence corresponds to SEQ ID NO: 2, a peptide which has at least 90% homology therewith, or fragments of the above, in the preparation of an immune response modulating agent. | 2009-10-22 |
20090263411 | Compositions, splice variants and methods relating to ovarian specific genes and proteins - The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and non-cancerous disease states in ovarian, identifying ovarian tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered ovarian tissue for treatment and research. | 2009-10-22 |
20090263412 | Non-Splicing Variants of gp350/220 - Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins. | 2009-10-22 |
20090263413 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND USE THEREOF IN PHARMACEUTICALS - A novel immunostimulatory oligonucleotide by which an IFN-inducing activity is enhanced and an inflammatory cytokine-inducing activity is reduced, and a pharmaceutical containing the same, and an application thereof are provided. That is, the present invention provides the immunostimulatory oligonucleotide composed of a base sequence represented by a formula: 5′-(G) | 2009-10-22 |
20090263414 | Bifunctional Protein Anchors - The invention relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allows the immobilization of any antigen of interest, without prior antigen modification. Provided is an antigen-loaded immunogenic carrier complex comprising at least one bifunctional polypeptide attached to an immunogenic carrier, said bifunctional polypeptide comprising a peptidoglycan binding domain (PBD) through which the polypeptide is attached to said carrier, fused to an antigen binding domain (ABD) to which at least one antigen of interest is bound. Also provided is a pharmaceutical (e.g. vaccine) composition comprising an antigen-loaded immunogenic carrier complex of the invention. | 2009-10-22 |
20090263415 | COMPOSITION FOR SCALP AND HAIR OF SCALP - An object of the present invention is to provide scalp and hair of scalp composition which realizes hair growing, hair growth or the like by arranging the scalp environment without inhibiting the function of sebaceous membrane and dark cell (superficial type cell) of scalp. To achieve the object, the present invention provides a composition which contains extraction component of fungi belonging to basidiomycetes and extraction component of the root of a plant of Araliceae. The composition may contain fats and fatty oils of | 2009-10-22 |
20090263416 | REDUCTION OF ANTIBIOTIC RESISTANCE IN BACTERIA - In one aspect of the present invention, a method is provided for reducing or eliminating antibiotic resistance in bacteria, comprising exposing the bacteria to a composition comprising a yeast cell wall preparation in an amount effective for reducing or eliminating resistance of the bacteria to at least one antibiotic. In one embodiment, the method comprises exposing the bacteria to the yeast cell wall preparation in an amount effective for eliminating a plasmid conferring resistance to the antibiotic, or for preventing transfer of the plasmid between bacteria. In another aspect, a method is provided for reducing prevalence of antibiotic-resistant bacteria in an animal, comprising administering to the animal a composition comprising a yeast cell wall preparation in an amount effective for reducing or eliminating the presence of an antibiotic-resistant bacterial population in the animal. | 2009-10-22 |
20090263417 | Multi-subtype FIV vaccines - The subject invention pertains to novel methods and compositions for protecting cats from infection by a broad range of FIV strains using a multi-subtype FIV vaccine. Multi-subtype FIV vaccines comprising either cell free whole virus or cell lines infected with viruses are described. Methods for vaccinating cats with the subject vaccine compositions are also described. Cats vaccinated according to the methods and compositions of the subject invention exhibit protective humoral and cellular immune responses to FIV when challenged with homologous or heterologous strains of FIV. The subject invention also pertains to novel feline cell lines that are susceptible to infection by FIV and their methods of use. | 2009-10-22 |
20090263418 | MEANS AND METHODS FOR MANIPULATING SEQUENTIAL PHAGOLYSOMALCYTOSOLIC TRANSLOCATION OF MYCOBACTERIA, AND USES THEREOF - Mycobacteria such as | 2009-10-22 |
20090263419 | Live attenuated bacterial vaccine - A live, attenuated bacterium of the genus | 2009-10-22 |
20090263420 | Virus-Like Particles As Vaccines For Paramyxovirus - The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines. | 2009-10-22 |
20090263421 | CELLULAR VACCINE - The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4 | 2009-10-22 |